The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IDYA | +25.15% | +152.77% | +20.38% | +198% |
| S&P | +13.66% | +87.02% | +13.34% | +136% |
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $207.83M | 0.0% |
| Gross Profit | $206.80M | 20535.2% |
| Gross Margin | 99.50% | 0.0% |
| Market Cap | $2.38B | -10.9% |
| Market Cap / Employee | $18.20M | 0.0% |
| Employees | 131 | 5.6% |
| Net Income | $119.24M | 330.1% |
| EBITDA | $109.48M | 266.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $298.93M | -25.3% |
| Accounts Receivable | $0.00M | -83.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $26.92M | 43.2% |
| Short Term Debt | $0.33M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -13.26% | 6.8% |
| Return On Invested Capital | -18.72% | 2.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $142.17M | 386.1% |
| Operating Free Cash Flow | $142.21M | 388.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.88 | 1.34 | 1.80 | 2.48 | -3.96% |
| Price to Sales | 320.67 | 206.75 | 265.67 | 11.36 | -98.37% |
| Price to Tangible Book Value | 1.88 | 1.34 | 1.80 | 2.48 | -3.96% |
| Enterprise Value to EBITDA | -11.06 | -9.38 | -13.89 | 15.35 | -155.29% |
| Return on Equity | -32.7% | -31.3% | -35.1% | -14.1% | -32.95% |
| Total Debt | $19.17M | $25.97M | $26.60M | $27.25M | 44.95% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
